Perceptions of Vaping Products

NCT06868368 | Completed

• 2 other identifiers: OSU-24276NCI-2024-10267
• Study Type: interventional
• Target: 53
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial studies the effects, appeal, and abuse liability of 6-methyl nicotine (metatine) electronic cigarettes among young adults.

Conditions

Abuse Tobacco; Exposure

Outcome Measures

Primary Outcomes (6)

• Pharmacokinetics of metatine and nicotine e-cigarettes

  Pharmacokinetics of metatine and nicotine e-cigarettes will be examined by measuring the concentration of metatine and nicotine in blood plasma at different timepoints throughout the study vaping session.

  Pre-vaping session, Minute 5 of vaping session, Minute 15 of vaping session, Minute 30 of vaping session

• E-cigarette puffing behavior

  E-cigarette puffing behavior will be measured with a topography device that records frequency, duration, and flow rate of e-cigarette puffs. These measures are combined to inform the overall measure of e-cigarette puffing behavior.

  Week 1, Week 2, Week 3

• Sensory perceptions of EC vaping experience

  Sensory perceptions of vaping will be measured by the Sensory E-cigarette Expectancies Scale (SEES) questionnaire. The SEES asks questions about sensory experiences associated with vaping on a scale from 0 (Never) - 4 (Almost Always).

  Minute 5 of vaping session, Minute 30 of vaping session

• Appeal ratings

  Participants will rate appeal (e.g., liking, disliking) on Visual Analogue Scales (range, 0-100).

  Minute 5 of vaping session, Minute 30 of vaping session

• Sensory ratings

  Participants will rate sensory attributes (e.g., harshness, coolness) on Visual Analogue Scales (range, 0-100).

  Minute 5 of vaping session, Minute 30 of vaping session

• Relief of withdrawal symptoms

  Nicotine withdrawal relief will be measured by the Minnesota Nicotine Withdraw Scale (MNWS). The MNWS asks users how much they are currently feeling certain nicotine withdraw symptoms on a scale of None, Slight, Moderate, Mild, or Severe.

  Pre-vaping session, Minute 5 of Vaping Session, Minute 30 of vaping session

Study Arms (3)

Participant's personal nicotine e-cigarette

ACTIVE COMPARATOR

The study participant's own preferred e-cigarette will be used for this condition.

Other: Biospecimen Collection; Other: Survey Administration; Behavioral: Vaping Topography; Other: Participant's Own Preferred E-cigarette

Nicotine e-cigarette

ACTIVE COMPARATOR

A fruit flavored commercially available nicotine e-cigarette will be used for this condition.

Other: Biospecimen Collection; Other: Survey Administration; Behavioral: Vaping Topography; Other: Nicotine E-cigarette

6-methyl nicotine (metatine) e-cigarette

ACTIVE COMPARATOR

A fruit flavored commercially available metatine e-cigarette will be used for this condition.

Other: Biospecimen Collection; Other: Survey Administration; Behavioral: Vaping Topography; Other: 6-methyl-nicotine (metatine) e-cigarette

Interventions

Biospecimen Collection OTHER

Undergo blood sample collection

Also known as: Biological Sample Collection

6-methyl nicotine (metatine) e-cigarette; Nicotine e-cigarette; Participant's personal nicotine e-cigarette

Survey Administration OTHER

Complete Surveys

6-methyl nicotine (metatine) e-cigarette; Nicotine e-cigarette; Participant's personal nicotine e-cigarette

Vaping Topography BEHAVIORAL

Use e-cigarette connected to a topography device

6-methyl nicotine (metatine) e-cigarette; Nicotine e-cigarette; Participant's personal nicotine e-cigarette

Participant's Own Preferred E-cigarette OTHER

Participant vapes their own preferred e-cigarette for 30 minutes

Participant's personal nicotine e-cigarette

Nicotine E-cigarette OTHER

Participant vapes a commercially available nicotine e-cigarette for 30 minutes

Nicotine e-cigarette

6-methyl-nicotine (metatine) e-cigarette OTHER

Participant vapes a commercially available metatine e-cigarette for 30 minutes

6-methyl nicotine (metatine) e-cigarette

Eligibility Criteria

• Age: 21 Years - 34 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Aged 21-34 years
• Current nicotine EC user (defined as ≥ weekly use over the past 3 months)
• Willing to provide informed consent and abstain from using any e-cigarette at least 12 hours prior to the three lab sessions
• Read and speak English

You may not qualify if:

• Recently coronavirus disease 2019 (COVID-19) positive (defined as a positive test in the past 30 days) or a recent COVID-19 hospitalization (defined as a hospitalization within the past 6 months)
• Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
• History of cardiac event or distress within the past 3 months
• Have suffered from any serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days
• Are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test)
• Have hemophilia or another type of bleeding disorder
• Are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability

Sponsors & Collaborators

• Ohio State University Comprehensive Cancer Center: lead

Study Sites (1)

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

Location

Related Links

• The Jamesline

MeSH Terms

Conditions

Tobacco Use Disorder

Interventions

Electronic Nicotine Delivery Systems

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Smoking Devices; Manufactured Materials; Technology, Industry, and Agriculture

Study Officials

• Alayna P Tackett, PhD

  Ohio State University Comprehensive Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Randomization to condition order will be completed prior to study Visit 1. Each participant will receive a randomized ordering developed using a random sequence generator.

Study Record Dates

• First Submitted: January 14, 2025
• First Posted: March 10, 2025
• Study Start: March 3, 2025
• Primary Completion: November 4, 2025
• Study Completion: November 4, 2025
• Last Updated: December 22, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)